Female infertility. Female infertility associated with anovulation
Conditions
Interventions
Intervention 1: First group, Minidose Agonist, receives GnRH Agonist (Bucerelin, Aventis, Germany) 50 µg subcutaneously from midluteal cycle (21th day). Ovarian stimulation is conducted by using Gonal
Siemens Medical Solutions, California, USA) is performed every 3 days. After the observation of at least two 18mm follicles, HCG (Ferring Co, Germany, 10000IU and IM) is injected and after 36 hours oo
the rate of fertilization, chemical and clinical pregnancy are compared between two groups. Intervention 2: Second group receives Decapeptyle 0.1mg (Ferring, Germany) in 3 consecutive days from the fi
Treatment - Drugs
First group, Minidose Agonist, receives GnRH Agonist (Bucerelin, Aventis, Germany) 50 µg subcutaneously from midluteal cycle (21th day). Ovarian stimulation is conducted by using Gonal F (Serono, Swit
Second group receives Decapeptyle 0.1mg (Ferring, Germany) in 3 consecutive days from the first day of menses. In the third day of menses ovarian stimulation is conducted by using Gonal F (Serono, Swi
Sponsors
Vice Chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 43 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Infertile women with at least two episodes of poor responses following maximal stimulation or at least two of the following three conditions: 1- Advanced maternal age (40 years old or greater) 2- A history of IVF failure ( retrieved 3 oocytes or less) 3- An abnormal ovarian reserve test (Antral Follicle Count 5 or lesser in early follicular phase or Antimulerian hormone less than 1mIU/ml) Exclusion Criteria: 1-Male infertility which needs interventions such as TESE (Testicular Sperm Extraction) or PESA (Percutaneous Epididymal Sperm Aspiration) 2- Endometriosis (stage 3 or 4) 3- Uterine myoma with 4cm size or greater 4- maternal age greater than 43 years old
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of retrieved oocytes. Timepoint: The day of oocyte retrieval. Method of measurement: Invert Microscope, Diaphot 300, Nikon, Japan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Chemical Pregnancy. Timepoint: 19 days after oocyte retrieval. Method of measurement: ßhCG titration.;The number of dominant follicles. Timepoint: 48 hours prior to oocyte retrieval. Method of measurement: Transvaginal ultrasonography.;The number and quality of embryos. Timepoint: 48 hours after oocyte retrieval. Method of measurement: Invert Microscope, Diaphot 300, Nikon, Japan.;Clinical pregnancy rate. Timepoint: 33 days after oocyte retrieval. Method of measurement: observed gestational sac in transvaginal sonography.;Fertilization Rate. Timepoint: The day after oocyte retrieval. Method of measurement: (Total number of embryos/ Total number of injected oocytes)* 100.;Cancellation rate of cycle. Timepoint: Any time. Method of measurement: the number of cycles not resulted in oocyte retrieval. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Sedighe Hoseinimosa
Tehran University of Medical Sciences, Shariati Hospital, Department of Infertility
Outcome results
None listed